There is a paucity of data regarding the association between glycosylated hemoglobin variability (HbA 1 c) and risk of microvascular complications in adolescents with type 1 diabetes (T1D).
T he Diabetes Control and Complications Trial (DCCT)
conclusively demonstrated the risk of microvascular complications rises markedly as glycosylated hemoglobin (HbA 1c ) increases (1) . However, even within the same mean HbA 1c levels, individuals can vary widely in their glycemic excursions, and more recent studies suggest visitto-visit variation in HbA 1c may be an additional risk factor for the development of retinopathy (2-4) and nephropathy (4, 5) in adults.
To date, however, there have been no studies assessing the association between HbA 1 c fluctuations and the risk of either peripheral or autonomic neuropathy. There is also a paucity of evidence on the relationship between HbA 1c variability and complications risk in children and adolescents with type 1 diabetes (5) . The clinical significance of HbA 1c variability is of particular interest in this group given their distinct risk factors for complications (eg, puberty) and the unique psychosocial and physiological challenges associated with the management of their glycemia (6) .
The objective of this study was thus to examine the association between HbA 1 c variability and the development of microvascular complications in a longitudinal cohort of young people with type 1 diabetes.
Research Design and Methods

Study Population
The study population consisted of adolescents with type 1 diabetes who were prospectively assessed for complications at The Children's Hospital at Westmead from January 1990 to May 2014. Inclusion criteria were age between 12 and 20 years, diabetes duration of at least five years, and availability of more than five serial HbA 1c measurements since diagnosis. This latter criterion was instituted as a larger number of HbA 1c measurements produce more reliable measures of glycemic variability (2, 7) . Ethics approval was obtained from The Sydney Children's Hospital Network Ethics Committee. Informed consent was obtained from all patients (and their families if aged Ͻ 18 years).
Assessment of Glycemic Variability
Glycemic control was assessed by measuring glycated hemoglobin (GHb) calorimetrically before February 1994 (8) and afterward by measurement of HbA 1c using high performance liquid chromatography (Diamat Bio-Rad analyzer, Bio-Rad, Herculus, CA; nondiabetic range 4%-6%). GHb values were converted to HbA 1c (Diamat ϭ 1.9088 ϩ 0.0043 x GHb; r ϭ 0.92) (9) .
For each patient, the intrapersonal mean and standard deviation (SD) of all recorded glycemic control measurements were calculated, and the SD-HbA 1c was considered a measure of glycemic variability. As the number of individual visits (n) could influence the SD-HbA 1c (with fewer visits likely to artificially inflate SD), values for SD-HbA 1c were divided by ͱ n n-1 to adjust for this possibility ( (4). We also calculated coefficient of variation (CV), a normalized measure of glycemic variability. CV was computed as the division of SD-HbA 1c by a factor of mean HbA 1 c (ie, CV ϭ SD-HbA1c MeanHbA1c/10 ).
Complications Assessment
Retinopathy was assessed by seven-field stereoscopic fundal photography using the IMAGEnet2000Lite system to digitalize images. The same ophthalmologist graded photographs according to the modified Airlie House classification (10) . Retinopathy was defined as the presence of at least one microaneurysm or hemorrhage (grade 21/10 or higher) in either eye.
Albumin excretion rate (AER) was determined using the mean of three consecutive timed overnight urine collections. Albumin was measured using Pharmacia Radioimmunoassay (Beckham Coulter Australia) before 2000, Immage Immunoassay (Beckham Coulter Australia) from 2000 to 2003, and Immulite Immunoassay (Simens Healthcare) thereafter. Regression equations for albumin had high correlation (R 2 ϭ 0.98; y-intercept of -0.5 and -0.56 mg/L). Albuminuria was defined as mean AER ug/min or mean ACR 2.8 mg/mmol (male) and 4.1 (female) (12) .
Peripheral nerve function was assessed by thermal threshold testing for hot and cold sensation at the dorsum of the left foot and vibration threshold testing at the left malleolus and left great toe (Neurosensory TSA-II and Vibratory Sensory Analyzer, Medoc Ltd, Ramat Yishai, Israel), as previously described (11) . Cardiac autonomic neuropathy (CAN) was assessed by measures of heart rate variability (HRV) obtained from analysis of 10-minute continuous electrocardiogram (ECG) recordings using the LabChart Pro (ADInstruments, Sydney, Australia). Derived timedomain measures included the standard deviation of mean NN intervals (where NN is the time between adjacent QRS complexes) and the root mean squared differences of successive NN intervals. Frequency-domain measures included low-frequency (LF) and high-frequency (HF) spectral components, and the LF: HF ratio. Together, these measures provide an estimate of both overall HRV and the relative parasympathetic and sympathetic balance (12) . Age-and gender-adjusted reference ranges used to define abnormality were derived from nondiabetic adolescent controls (9) . Peripheral neuropathy was defined as either a vibration or thermal threshold test score above the 95th percentile. Cardiac autonomic neuropathy was defined as a measurement below the fifth percentile on at least one time-domain or frequency-domain measure ofHRV.
Height, weight and BMI from each complications assessment were converted to z scores using the 2000 Centers for Disease Control (CDC) reference standards (13) . Systolic and diastolic blood pressure (BP) (SBP and DBP) z scores for age and sex were derived using the U.S. Task Force Report (14) . Cholesterol was measured using a Beckman CX5 from 1990 -1999, a Dimension RXL from 2000 -2005 and a Vitros analyzer (Ortho Clinical Diagnostics) thereafter. Participants were classified into either a socioeconomically disadvantaged (deciles 1-3) or socioeconomically advantaged (deciles 4 -10) group using a postcode-based system derived from the Australian Bureau of Statistics SocioEconomic Indexes for Areas (SEIFA) database (15) .
Statistical Analysis
Descriptive statistics are reported using means SD for normally distributed continuous variables, and median [interquartile range] for skewed data. Differences between two groups were analyzed using Independent Samples t test for normally distributed variables and the Mann-Whitney U test for skewed data. Trends across more than two groups were analyzed using linear polynomial contrasts (ANOVA) for normally distributed variables and the Jonckheere-Terpstra test for skewed data. Categorical variables were compared using Pearson's 2 or linearby-linear association test (trend across more than two groups). Multiple linear regression was used to identify baseline factors associated with glycemic variability, after applying a natural logarithmic transformation to SD-HbA 1c .
To longitudinally examine the association between glycemic variability and microvascular complications, generalized estimating equations were used so that correlations between repeat visits for an individual patient could be taken into account (16) . Regression models were adjusted for the following covariates: mean HbA 1c (%), age (years), sex, diabetes duration (years), SBP and DBP (z scores), cholesterol (mmol/L), height (z score), BMI (z score) and socioeconomic disadvantage. Spearman's rank correlation coefficient (r s ) was used to assess strength of association between covariates and screen for collinearity.
To account for the possible influence of mean HbA 1c on SDHbA 1c , two models were constructed. Model 1 used SD-HbA 1c as a measure of glycemic variability while Model 2 used HbA 1 c. Clinically relevant interaction terms (eg, age*SD-HbA 1c , age*CV, sex*SD-HbA 1c , sex*CV, duration*SD-HbA 1c , duration*CV, age*sex*SD-HbA 1c , age*sex*CV, duration*sex*SD-HbA 1c , duration*sex*CV) were not significant, and were excluded from the final models. Quadratic terms for SD-HbA 1c and CV used to test for curvature were not significant. The Quasi Likelihood Under Independence Model Criterion (QIC) was used to summarize goodness of fit of multivariable models, and assess the added predictive value of glycemic variability (18) . Results are reported as odds ratios (ORs) with 95% confidence intervals (CI). SPSS version 22.0 (IBM, Armonk, NY) was used for statistical analysis.
Results
Overall, 1 706 patients (47% male) met the inclusion criteria and results from 3 995 complications assessments were included in the analysis. Those excluded due to the lack of serial HbA 1c measurements (n ϭ 301) had significantly shorter diabetes duration (median 7.1 vs. 8.1 year; P Ͻ .001) but were not significantly different in regards to proportion male, socioeconomic disadvantage, insulin dose, BP, cholesterol, or BMI SDS.
Median age at last assessment was 15. Patient characteristics and complication rates at last assessment are presented in Table 1 , stratified by ascending quartiles of SD-HbA 1c . Those with higher SD-HbA1c were older, had longer diabetes duration, shorter stature, higher daily insulin dose, mean HbA 1c , BP (z scores) and cholesterol, and were less likely to be treated with intensive insulin therapy.
The prevalence of retinopathy, albuminuria and cardiac autonomic neuropathy (CAN) increased significantly across ascending quartiles of SD-HbA 1c (Table 1 , Figure  1 ). Patients in higher quartiles of SD-HbA 1c displayed significantly higher median AER. However, no trend was observed for peripheral neuropathy. Table 2 shows the relationship between glycemic variability and the development of microvascular complications after adjusting for mean HbA 1c and other covariates, using generalized estimating equations. Model 1 included SD-HbA 1c while Model 2 included HbA 1c CV. Using either measure, greater glycemic variability was associated with the development of retinopathy, albuminuria, increased log 10 AER and CAN after adjustment for known risk factors. A one-unit increase in SD-HbA 1c was associated with 32% higher odds of retinopathy, 81% higher odds of albuminuria, 128% higher odds of CAN and 10% increase in log 10 AER. For each of these outcomes, the addition of either SD-HbA 1c or CV improved the goodness of fit of the multivariable models (Table 3 ). There was no association between peripheral neuropathy and glycemic variability (as measured by either SD-HbA 1c or CV).
Conclusions
In this observational study involving 1 706 adolescents with type 1 diabetes, HbA 1c variability was significantly associated with an increased risk of retinopathy, albuminuria, elevated albumin excretion rate and CAN after adjusting for established risk factors. This is the first time that glycemic variability has been associated with CAN. While our results for retinopathy and early nephropathy are consistent with a recent analysis of the DCCT (4) as well as several cohort studies involving adults with type 1 diabetes (2, 3, 17) , we demonstrate the association between HbA 1c instability and these complications in an adolescent population, in whom such clinical data had been scarce (5) . Moreover, in contrast to the more advanced endpoints employed in previous studies, we defined retinopathy as a one-level worsening on the Early Treatment Diabetic Retinopathy Scale and examined early elevation of AER, which predicts future development of microalbu-
press.endocrine.org/journal/jcemminuria (18) . Thus, by employing earlier clinical endpoints, we have demonstrated the association with HbA 1c variability applies across the entire spectrum of retinal and renal disease. Our most novel finding was the significant association between glycemic variability and CAN. A one-unit increase in SD-HbA 1c more than doubled the odds of CAN. The effect size was greater than that observed for any other microvascular complication, and is of substantial clinical significance considering that CAN is linked with increased mortality and a higher risk of sudden cardiac death (19) . Furthermore, in the case of CAN, the impact of glycemic variability was considerably greater than that of mean HbA 1c , which had a comparatively modest effect (Table  2 ). This raises the question of whether fluctuations in glycemia may play a greater role in the development of CAN than hyperglycemia itself.
In contrast, peripheral neuropathy was not associated with HbA 1c variability. The conflicting results for autonomic and peripheral neuropathy are particularly surprising given the strong epidemiological data supporting their shared association with hyperglycemia and other metabolic risk factors (20, 21) . The negative finding for peripheral neuropathy is almost certainly not a chance result considering both the point estimate of the odds ratio (OR) and the value of the significance test approach unity. Moreover, given the large sample size and relatively high event rate, the analysis was sufficiently powered to detect even a weak association. These results may instead reflect differences in the sensitivity of autonomic and peripheral nerves or the effect of unknown confounders that were not adjusted for in the present study.
There are several possible explanations for the association observed between glycemic variability and increased complications risk. There may be underlying confounders driving this relationship, such as the effect of residual ␤-cell function and endogenous insulin secretion, which is plausible considering glycemic variability may directly contribute to ␤-cell apoptosis (23) . Alternatively, comorbidities and factors affecting treatment compliance may have contributed to both higher glycemic variability and an increased risk of microvascular complications in this cohort.
It has been hypothesized that fluctuations in HbA 1 c independently contribute to increased oxidative stress, which plays a key role in the pathogenesis of diabetic complications (4, 22) . This relationship between HbA 1c variability and oxidative stress is extrapolated from animal and in vitro studies that show increased superoxide production in the setting of higher short-term (within-day) glucose variability (23) (24) (25) . However, in studies of individuals with type 1 diabetes, short-term glucose variability is not associated with oxidative stress (26) or the risk of microvascular complications (27) (28) (29) (30) . Other putative mechanisms include the induction of inflammatory cytokines (33) or stimulation of epigenetic changes that may promote systemic inflammation (34) .
Another possible underlying mechanism may be the "normoglycemic re-entry phenomenon." whereby retinopathy frequently worsens following a reduction in HbA 1c , before improving as glycemic control is maintained (31) . However, patients with widely fluctuating HbA 1c may be caught in a cycle where the transient worsening associated with periods of low glycemia is followed by hyperglycemia-induced damage, and vice versa. Although this phenomenon has been mainly observed for retinopathy, homeostatic disturbances caused by an unstable glycemic environment may also be detrimental for other complications (17) . Alternatively, the association with HbA 1c variability may be related to the "metabolic memory" hypothesis, which proposes that periods of hyperglycemia are "remembered" in the organs in which microvascular disease later occurs. This is supported by data from the Epidemiology of Diabetes Intervention and Complications (EDIC) study demonstrating early glycemic control is a key determinant of future complications risk (32) (33) (34) (35) . Moreover, the metabolic memory effect is weakest forperipheral neuropathy, which may partially explain its lack of an association with glycemic variability in the present study (36) .
Our findings have several implications for clinical prac- tice. From a prognostic standpoint, we have demonstrated a more complete and informative assessment of both glycemic control and complications risk can be obtained by also considering a measure of glycemic variability. mol-)Moreover, although this was not an interventional study, we found the use of intensive insulin therapy was strongly associated with lower glycemic variability. This implies intensive regimens may provide additional protection beyond their role in reducing HbA 1c and extends our previous observations that intensive insulin therapy is associated with a lower risk of microvascular complications in adolescents (12) (38) . The possibility of dual protection is appealing as reduction of HbA 1c alone is difficult in practice, with fewer than half of all patients able to maintain levels below the pediatric target of 7.5% (58 mmol/mol) (37). Our findings may be limited by several factors. Firstly, the number of measurements per patient varied, so to minimize this potential bias, we divided SD-HbA 1c by a function of the number of measurements. Secondly, although correlation testing did not suggest prohibitive collinearity, it is possible that the presence of both mean HbA 1 c and SD-HbA 1 c in regression models may have artificially inflated the significance of one, or both, of these variables. Thirdly, there were fewer patients included in the analysis of CAN as HRVtesting was only available in more recent years. However, it is unclear how this temporal bias could have systematically favored an association between glycemic variability and CAN. Further research is required to elucidate the precise mechanisms mediating the association between HbA 1c variability and complications risk, and to clarify why studies investigating short-term glucose variability have produced discrepant results. Future studies may also extend press.endocrine.org/journal/jcem
